Status:
COMPLETED
Dosimetry of [11C]CHDI-180R and [11C]CHDI-626.
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Collaborating Sponsors:
CHDI Foundation, Inc.
Conditions:
Huntington Disease
Eligibility:
All Genders
18-55 years
Brief Summary
A better understanding of the HD pathogenesis mechanisms may lead to a better understanding of disease pathology, progression and development of targeted therapies. \[11C\]CHDI-00485180-R and \[11C\]...
Detailed Description
For both groups, the dynamic whole-body distribution of the respective tracer labelled with \[11C\] will be measured after IV administration of 370 MBq. Two venous catheters, one on each arm, will be ...
Eligibility Criteria
Inclusion
- Male or female subjects, age between 18 and 55 years old
- Subject is judged to be in good health by the investigator on the basis of medical history. When still in doubt, a full physical and neurological examination can be conducted
Exclusion
- Subject has a history of major internal disease that may interfere with the investigations (especially liver and kidney disease, cancer or uncontrolled diabetes).
- Subject has any history of a major neurological or psychiatric disorder
- Subject is currently smoker (\> 20 cigarettes or equivalent/day) a user (including ''recreational use'') of any illicit drugs, including cannabis, or has a history of drug or alcohol abuse.
- Subject has had exposure to ionizing radiation (\> 1 mSv) in other research studies within the last 12 months.
- Subject suffers from claustrophobia or cannot tolerate confinement during PET-CT scanning procedures; subject cannot lie still for 90 minutes inside the scanner.
- Subject is unwilling to avoid unusual, unaccustomed, or strenuous physical activity (i.e. weight lifting, running, bicycling) 3 days before and during the day of scanning.
- Subject does not understand the study procedure
- Subject is unwilling or unable to perform all of the study procedures, or is considered unsuitable in any way by the principal investigator.
- Subject is potentially pregnant (hCG will be performed in women with childbearing potential).
- Allergy for local anesthesia (lidocaine)
Key Trial Info
Start Date :
July 17 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 13 2020
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT05224115
Start Date
July 17 2020
End Date
October 13 2020
Last Update
May 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UZ Leuven
Leuven, Belgium, 3000